AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. The organization's mission is to recognize excellence, advance the public understanding, and accelerate medical and biological innovation
FREMONT, CA: The American Institute for Medical and Biological Engineering (AIMBE) announced the induction of Joerg Breitenbach, Ph.D., MBA, Founder and Scientific Advisor, BIT Pharma to its College of Fellows. The election to the AIMBE College of Fellows is considered to be one of the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers.
AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. The organization's mission is to recognize excellence, advance the public understanding, and accelerate medical and biological innovation. AIMBE holds a unique position that allows them to bring together academic, industry, government, and scientific societies to form a highly influential community advancing medical and biological engineering. The organization's mission drives advocacy initiatives into action on Capitol Hill and beyond.
The College membership honors personnel who have made outstanding contributions to the field of engineering and medicine research, practice, or education and to the pioneering of new and developing fields of technology, making significant advancements in traditional areas of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.
Dr. Joerg Breitenbach is a General Manager at BIT Pharma, a biotech firm with a revolutionary approach to overcoming the blood-brain barrier in the delivery of voltage-gated calcium channel antagonists. "BIT Pharma takes pride in its drug delivery system called AIMEX that can successfully carry very different molecules to the brain, without hindering the function of any vessel. The same system can deliver both small molecules and biologics to the brain, which can prove beneficial for some rare diseases," said Dr. Breitenbach.
Dr. Breitenbach was nominated, reviewed, and elected by peers and members of the College of Fellows for outstanding contributions in the development and commercialization of patient-centric polymer-based dosage forms in infectious diseases and neurological interventions. Due to the rising health concerns caused by the COVID-19 pandemic, AIMBE’s annual meeting and induction ceremony scheduled for March 29 and 30 was canceled. Under special procedures, Dr. Breitenbach was remotely inducted along with 156 colleagues who make up the AIMBE College of Fellows Class of 2020.